| Literature DB >> 31527478 |
Yinjiao Li1, Luying Shan2, Chen Zhang3, Zhan Lei4, Ying Shang5,6.
Abstract
We assessed the prevalence of antibiotic resistant and antibiotic resistance genes for 49 Tetragenococcus halophilus (T. halophilus) strains isolated from Xuawei ham in China. The antibiotic resistance phenotype was detected by the Bauer-Kirby (K-B) method and the results showed that 49 isolates can be considered completely susceptible to penicillin, ampicillin, amoxicillin, cefradine, cefotaxime, tetracyclines, minocycline, doxycycline, and vancomycin, but resistant to gentamicin, streptomycin, neomycin, polymyxinB, cotrimoxazole. This resistance was sufficiently high to consider the potential for acquisition of transmissible determinants. A total of 32 isolates were resistant to ofloxacin, 4 isolates were resistant to ciprofloxacin and chloramphenicol, and 2 isolates were resistant to ceftazidime and ticarcillin. The antibiotic resistance genes were detected by routine polymerase chain reaction (PCR). Among the 26 antibiotic resistance genes, 5 varieties of antibiotic resistance genes, including acrB, blaTEM, AAda1, SulII, and GyrB were detected and the detection rates were 89.79%, 47.7%, 16.33%, 77.55%, and 75.51%, respectively. The potential acquisition of transmissible determinants for antibiotic resistance and antibiotic resistance genes identified in this study necessitate the need for a thorough antibiotic resistance safety assessment of T. halophilus before it can be considered for use in food fermentation processes.Entities:
Keywords: Tetragenococcus halophilus; Xuanwei ham; antibiotic resistance genes; antibiotic resistant
Year: 2019 PMID: 31527478 PMCID: PMC6783965 DOI: 10.3390/antibiotics8030151
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Partial electropherogram result of genomic DNA of isolated strains. M: DNA Maker DL2000; Lanes 5–49: DNA bands of 10 isolated strains.
Figure 2The PCR (polymerase chain reaction) results of the screened T. halophilus strains. (A) The screened T. halophilus strains by amplification of groEL gene; Lane M: DNA Marker DL2000; Lane 0: negative; Lane 1–23: Candidate strain of T. halophilus; (B) Electrophoresis of amplification product; Lane M: DNA Maker; Lane 0: Negative control; Lanes 1–23: The band of PCR amplification products of DNA primer PCR.
Figure 3Phylogenetic analysis of 49 strains of T halophilus based on 16S rRNA sequence.
Pharmacokinetic phenotypic test results of 49 strains of T. halophilus.
| Antibiotic | Isolates of Resistant | Isolates of Susceptible | Resistance Rate (R) | Intermediate Rate (I) | Susceptible Rate (S) | |||
|---|---|---|---|---|---|---|---|---|
| PEN | 0 | 49 | 0% | (0/49) | 0% | (0/49) | 100% | (49/49) |
| AMO | 0 | 47 | 0% | (0/49) | 4.08% | (2/49) | 95.90% | (47/49) |
| AMP | 0 | 49 | 0% | (0/49) | 0% | (0/49) | 100% | (49/49) |
| TIC | 2 | 47 | 4.08% | (2/49) | 0% | (0/49) | 95.9% | (47/49) |
| CE | 0 | 49 | 0% | (0/49) | 0% | (0/49) | 100% | (49/49) |
| CAZ | 2 | 42 | 4.08% | (2/49) | 10.20% | (5/49) | 85.70% | (42/49) |
| CTX | 0 | 49 | 0% | (0/49) | 0% | (0/49) | 100% | (49/49) |
| GEN | 49 | 0 | 100% | (49/49) | 0% | (0/49) | 0% | (0/49) |
| STR | 49 | 0 | 100% | (49/49) | 0% | (0/49) | 0% | (0/49) |
| NE | 49 | 0 | 100% | (49/49) | 0% | (0/49) | 0% | (0/49) |
| TET | 0 | 49 | 0% | (0/49) | 0% | (0/49) | 100% | (0/49) |
| MH | 0 | 49 | 0% | (0/49) | 0% | (0/49) | 100% | (0/49) |
| DO | 0 | 49 | 0% | (0/49) | 0% | (0/49) | 100% | (0/49) |
| PB | 49 | 0 | 100% | (49/49) | 0% | (0/49) | 0% | (0/49) |
| VA | 0 | 49 | 0% | (0/49) | 0% | (0/49) | 100% | (0/49) |
| COM | 49 | 0 | 100% | (0/49) | 0% | (0/49) | 0% | (0/49) |
| CHL | 4 | 40 | 8.16% | (0/49) | 10.20% | (5/49) | 81.63% | (40/49) |
| OFZ | 32 | 2 | 65.31% | (32/49) | 30.61% | (15/49) | 4.08% | (2/49) |
| CIP | 4 | 33 | 8.16% | (4/49) | 24.49% | (12/49) | 67.35% | (33/49) |
Figure 4Distribution of drug resistance of 49 strains of T. halophilus. (A) Number of bacterial strains —by type of antibiotic; (B) Number of bacterial strains —by categories of antibiotic.
Drug resistance spectrum of 49 strains of T. halophilus.
| Type of Resistance | Resistant Spectrum | Isolates |
|---|---|---|
| 5 | GEN-STR-NEO-PB-COM | 49 |
| 6 | GEN-STR-NEO-PB-COM-OFZ | 32 |
| 7 | GEN-STR-NEO-PB-COM-OFZ-CIP | 4 |
| GEN-STR-NEO-PB-COM-OFZ-CAZ | 2 | |
| GEN-STR-NEO-PB-COM-OFZ-TLC | 2 | |
| GEN-STR-NEO-PB-COM-OFZ-CHL | 2 | |
| 8 | GEN-STR-NEO-PB-COM-OFZ-CIP-CHL | 4 |
| GEN-STR-NEO-PB-COM-OFZ-CIP-CAZ | 1 |
Multi-drug resistance of 49 strains of T. halophilus.
| Type of Resistance | Number of Isolates | Proportion (%) |
|---|---|---|
| 0 | 0 | 0 |
| 1 | 49 | 100% |
| 2 | 49 | 100% |
| 3 | 49 | 100% |
| 4 | 49 | 100% |
| 5 | 49 | 100% |
| 6 | 32 | 65.31% |
| 7 | 12 | 24.50% |
| 8 | 5 | 10.20% |
Figure 5PCR detection results of some T. halophilus resistance genes. (A) blaTEM gene; (B) GyrB gene; (C) SulII gene; (D) EmgrB gene; (E) acrB gene; (F) aadA1 gene; M: DL2000Marker, 0: Negative control.
Detection rate of 26 drug resistance genes in 49 strains of T. halophilus.
| Antibiotic | AR Gene | Positive Isolates | Totally Isolates | Positive Rates |
|---|---|---|---|---|
| Tetracyclines |
| 0 | 49 | 0% |
|
| 0 | 49 | 0% | |
|
| 0 | 49 | 0% | |
|
| 0 | 49 | 0% | |
|
| 0 | 49 | 0% | |
|
| 0 | 49 | 0% | |
|
| 8 | 49 | 16.33% | |
|
| 0 | 49 | 0% | |
|
| 0 | 49 | 0% | |
|
| 0 | 49 | 0% | |
| Sulfonamides |
| 0 | 49 | 0% |
|
| 38 | 49 | 77.55% | |
|
| 0 | 49 | 0% | |
| Aminoglycosides |
| 0 | 49 | 0% |
|
| 44 | 49 | 89.79% | |
|
| 0 | 49 | 0% | |
|
| 14 | 49 | 28.57% | |
| Chloram Phenicols |
| 0 | 49 | 0% |
|
| 0 | 49 | 0% | |
| Quinolones |
| 0 | 49 | 0% |
|
| 37 | 49 | 75.51% | |
|
| 0 | 49 | 0% | |
| Polypeptide Antibiotic |
| 0 | 49 | 0% |
|
| 30 | 49 | 61.22% |
Figure 6Gene mechanism. (A) Inherent drug resistance. Resistance genes exist in bacteria and are passed on from generation to generation. (B) Gene mutation or acquisition of new genes. Pressure to increase antibiotic production causes bacteria to mutate genes into drug resistance and, at the same time, bacteria can easily acquire resistance by ingesting resistance genes released after the death of another drug-resistant bacteria. (C) Integrons mediate drug resistance. Under the catalysis of integrase, integrons can capture and express exogenous genes, especially drug-resistant genes, so that drug-resistant genes can be transmitted between different species.
Figure 7Biochemical (protein) mechanism. (A) Production of inactivated or modified enzymes. (B) Change of target site or generation of new target site. This makes is difficult for antibiotics to bind to cells, thus reducing the inhibitory effect of antibiotics. (C) Changes of outer membrane protein. Long-term drug effects can stimulate adventitia proteins to alter the cell wall structure and reduce permeability, thus hindering the penetration of antibiotics. (D) Active efflux system. When energy is available, membrane proteins selectively or non-selectively expel antibiotics from the cell, reducing drug concentration and leading to drug resistance.
Drug-resistant phenotype and genotype coincidence rate of T. halophilus.
| Antibiotic | Resistant Phenotype | Resistant Gene | Compliance Rate (%) | |
|---|---|---|---|---|
| Tetracyclines | 0 | 0 | (0/0) | 100% |
| 5 | 8 | (5/8) | 62.5% | |
| Sulfonamides | 49 | 38 | (38/49) | 79.17% |
| Aminoglycosides | 49 | 45 | (45/49) | 91.84% |
| Chloram phenicols | 4 | 0 | 0 | 0 |
| Quinolones | 32 | 37 | (32/37) | 86.49% |
| Polypeptide Antibiotic | 49 | 30 | (30/49) | 61.22% |
Primers sequences of PCR amplification.
| Primers | Gene Sequences (5’–3’) | References |
|---|---|---|
| 27-F | AGATTTGATCCTGGCTCAG | [ |
| 1492-R | CTACGGCTACCTTGTTACGA | |
| GroEL-F | CGTCGTCAATGCTYAATGG | [ |
| GroEL-R | TGCTGCCAGAAGAAACTTCA |
Primers sequences of PCR amplification.
| Antibiotic | AR Gene | Gene Sequences (5‘–3‘) | Annealing Temp. (°C) | Product Size (bp) | Ref. |
|---|---|---|---|---|---|
| Tetracyclines |
| F: TTAGGTGAAGGGTTAGGTCC | 59 | 697 | [ |
|
| F: AACTTAGGCATTCTGGCTCAC | 55 | 515 | [ | |
|
| F: CATTTGGTCTTATTGGATCG | 55 | 456 | [ | |
|
| F: GAGAGCCTGCTATATGCCAGC | 58 | 168 | [ | |
|
| F: TCATCATCTCCTGATTTTAC | 60 | 1464 | This study | |
|
| F: GTTAAATAGTGTTCTTGGAG | 53 | 501 | This study | |
|
| F: CAGAAACGCTGGTGAAAG | 54 | 788 | [ | |
|
| F: TTGGTCTACATGACCGCGTCTGTA | 59 | 623 | This study | |
|
| F: TTTTCTGTTGTTTGGGTTTC | 53 | 447 | [ | |
|
| F: TGTATTATCTCCCTGTTAGC | 55 | 843 | [ | |
| Sulfonamides |
| F: TCGGACAGGGCGTCTAAG | 63 | 925 | [ |
|
| F: CCTGTTTCGTCCGACACAGA | 55 | 435 | This study | |
|
| F: ATGAGCAAGATTTTTGGAATCGTA | 59 | 792 | [ | |
| Aminoglycosides |
| F: GGCGACTTCACCGTTTCT | 54 | 412 | [ |
|
| F: CGTGAGCGTTGAGAAGTCCT | 58 | 222 | [ | |
|
| F: GAGGAGTTGGACTATGGATT | 53 | 208 | This study | |
|
| F: TTTGCTGGTTACGGTGAC | 58 | 497 | [ | |
| Chloramphenicols |
| F: GAACACGACGCCCGCTAT | 54 | 601 | [ |
|
| F: AGTGGAATAACGAACGAGC | 57 | 470 | This study | |
| Quinolones |
| F: GGTGACGTAATCGGTAAATA | 53 | 810 | [ |
|
| F: GGACAAAGAAGGCTACAGCA | 53 | 879 | [ | |
|
| F: CTGGGTAAATACCATCCGCAC | 53 | 987 | [ | |
| Polypeptides |
| F: GGTATCAAGGAAACCTC | 55 | 822 | [ |
|
| F: CCGCTGAGTAATAATCCTAT | 48 | 492 | [ |